Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot study

What Was Tested

This randomized controlled trial paper looks at hCG (human chorionic gonadotropin) in the context of endometriosis.

More than 3 days' luteal endometrial advancement in IVF has been related with no pregnancies.

This study assessed the effect of recombinant and urinary human chorionic gonadotrophin (recHCG and uHCG) when administered for final oocyte maturation on the advancement of endometrial histology.

Who Took Part

The study group was 13 patients.

PubMed indexes the participants as adults, women only.

All specimens were evaluated according to Noyes' criteria by one pathologist blinded to the allocation treatment groups.

How the Study Was Run

The researchers set it up as a randomized and pilot study.

Random assignment meant chance, not the researchers, decided who got hCG (human chorionic gonadotropin) and who got the comparison, which limits bias.

It is described as a pilot, a small early test of whether a larger hCG (human chorionic gonadotropin) study would be practical.

What Was Measured

This study assessed the effect of recombinant and urinary human chorionic gonadotrophin (recHCG and uHCG) when administered for final oocyte maturation on the advancement of endometrial histology.

PubMed files the paper under topics including Biopsy, Chorionic Gonadotropin, Endometrium, Oocyte Retrieval, Ovulation Induction, Pilot Projects and Pregnancy Outcome.

What This Means in Plain Language

The paper is a randomized and pilot study of hCG (human chorionic gonadotropin) in 13 patients in people with endometriosis.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2010 (Reproductive biomedicine online), a journal based in Netherlands.

More context: the hCG (human chorionic gonadotropin) compound page, Endometriosis research.